Congratulations to Spyre Therapeutics on its NASDAQ debut! Spyre is the second company founded upon potentially best-in-class antibodies discovered and developed by Paragon and is working to transform the treatment of patients with #IBD. We celebrate this achievement alongside CEO Cameron Turtle and the full Spyre team and look forward to future milestones. #biotechnology $SYRE
It's official! Tomorrow Spyre Therapeutics makes its debut on NASDAQ as "SYRE". Our commitment is to developing next generation therapeutics for people living with IBD, including ulcerative colitis (UC) and Crohn’s disease (CD). Follow up to keep up to date on our journey and visit our website: www.spyre.com #biotech #immunology #crohnsdisease #ulcerativecolitis #$SYRE